1
|
Arman S, Tilley RD, Gooding JJ. A review of electrochemical impedance as a tool for examining cell biology and subcellular mechanisms: merits, limits, and future prospects. Analyst 2024; 149:269-289. [PMID: 38015145 DOI: 10.1039/d3an01423a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2023]
Abstract
Herein the development of cellular impedance biosensors, electrochemical impedance spectroscopy, and the general principles and terms associated with the cell-electrode interface is reviewed. This family of techniques provides quantitative and sensitive information into cell responses to stimuli in real-time with high temporal resolution. The applications of cell-based impedance biosensors as a readout in cell biology is illustrated with a diverse range of examples. The current state of the field, its limitations, the possible available solutions, and the potential benefits of developing biosensors are discussed.
Collapse
Affiliation(s)
- Seyedyousef Arman
- School of Chemistry, The University of New South Wales, Sydney, New South Wales 2052, Australia.
- Australia Centre for Nanomedicine, The University of New South Wales, Sydney, New South Wales 2052, Australia
| | - Richard D Tilley
- School of Chemistry, The University of New South Wales, Sydney, New South Wales 2052, Australia.
- Electron Microscope Unit, Mark Wainwright Analytical Centre, The University of New South Wales, Sydney, New South Wales 2052, Australia
| | - J Justin Gooding
- School of Chemistry, The University of New South Wales, Sydney, New South Wales 2052, Australia.
- Australia Centre for Nanomedicine, The University of New South Wales, Sydney, New South Wales 2052, Australia
| |
Collapse
|
2
|
Chauhan S, Khasa YP. Challenges and Opportunities in the Process Development of Chimeric Vaccines. Vaccines (Basel) 2023; 11:1828. [PMID: 38140232 PMCID: PMC10747103 DOI: 10.3390/vaccines11121828] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2023] [Revised: 07/22/2023] [Accepted: 08/04/2023] [Indexed: 12/24/2023] Open
Abstract
Vaccines are integral to human life to protect them from life-threatening diseases. However, conventional vaccines often suffer limitations like inefficiency, safety concerns, unavailability for non-culturable microbes, and genetic variability among pathogens. Chimeric vaccines combine multiple antigen-encoding genes of similar or different microbial strains to protect against hyper-evolving drug-resistant pathogens. The outbreaks of dreadful diseases have led researchers to develop economical chimeric vaccines that can cater to a large population in a shorter time. The process development begins with computationally aided omics-based approaches to design chimeric vaccines. Furthermore, developing these vaccines requires optimizing upstream and downstream processes for mass production at an industrial scale. Owing to the complex structures and complicated bioprocessing of evolving pathogens, various high-throughput process technologies have come up with added advantages. Recent advancements in high-throughput tools, process analytical technology (PAT), quality-by-design (QbD), design of experiments (DoE), modeling and simulations, single-use technology, and integrated continuous bioprocessing have made scalable production more convenient and economical. The paradigm shift to innovative strategies requires significant attention to deal with major health threats at the global scale. This review outlines the challenges and emerging avenues in the bioprocess development of chimeric vaccines.
Collapse
Affiliation(s)
| | - Yogender Pal Khasa
- Department of Microbiology, University of Delhi South Campus, New Delhi 110021, India;
| |
Collapse
|
3
|
Kilgore R, Minzoni A, Shastry S, Smith W, Barbieri E, Wu Y, LeBarre JP, Chu W, O'Brien J, Menegatti S. The downstream bioprocess toolbox for therapeutic viral vectors. J Chromatogr A 2023; 1709:464337. [PMID: 37722177 DOI: 10.1016/j.chroma.2023.464337] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2023] [Revised: 08/24/2023] [Accepted: 08/27/2023] [Indexed: 09/20/2023]
Abstract
Viral vectors are poised to acquire a prominent position in modern medicine and biotechnology owing to their role as delivery agents for gene therapies, oncolytic agents, vaccine platforms, and a gateway to engineer cell therapies as well as plants and animals for sustainable agriculture. The success of viral vectors will critically depend on the availability of flexible and affordable biomanufacturing strategies that can meet the growing demand by clinics and biotech companies worldwide. In this context, a key role will be played by downstream process technology: while initially adapted from protein purification media, the purification toolbox for viral vectors is currently undergoing a rapid expansion to fit the unique biomolecular characteristics of these products. Innovation efforts are articulated on two fronts, namely (i) the discovery of affinity ligands that target adeno-associated virus, lentivirus, adenovirus, etc.; (ii) the development of adsorbents with innovative morphologies, such as membranes and 3D printed monoliths, that fit the size of viral vectors. Complementing these efforts are the design of novel process layouts that capitalize on novel ligands and adsorbents to ensure high yield and purity of the product while safeguarding its therapeutic efficacy and safety; and a growing panel of analytical methods that monitor the complex array of critical quality attributes of viral vectors and correlate them to the purification strategies. To help explore this complex and evolving environment, this study presents a comprehensive overview of the downstream bioprocess toolbox for viral vectors established in the last decade, and discusses present efforts and future directions contributing to the success of this promising class of biological medicines.
Collapse
Affiliation(s)
- Ryan Kilgore
- Department of Chemical and Biomolecular Engineering, North Carolina State University, Raleigh, NC 27695, United States.
| | - Arianna Minzoni
- Department of Chemical and Biomolecular Engineering, North Carolina State University, Raleigh, NC 27695, United States
| | - Shriarjun Shastry
- Department of Chemical and Biomolecular Engineering, North Carolina State University, Raleigh, NC 27695, United States; Biomanufacturing Training and Education Center (BTEC), North Carolina State University, Raleigh, NC 27695, United States
| | - Will Smith
- Department of Chemical and Biomolecular Engineering, North Carolina State University, Raleigh, NC 27695, United States
| | - Eduardo Barbieri
- Department of Chemical and Biomolecular Engineering, North Carolina State University, Raleigh, NC 27695, United States
| | - Yuxuan Wu
- Department of Chemical and Biomolecular Engineering, North Carolina State University, Raleigh, NC 27695, United States
| | - Jacob P LeBarre
- Department of Chemical and Biomolecular Engineering, North Carolina State University, Raleigh, NC 27695, United States
| | - Wenning Chu
- Department of Chemical and Biomolecular Engineering, North Carolina State University, Raleigh, NC 27695, United States
| | - Juliana O'Brien
- Department of Chemistry, North Carolina State University, Raleigh, NC 27695, United States
| | - Stefano Menegatti
- Department of Chemical and Biomolecular Engineering, North Carolina State University, Raleigh, NC 27695, United States; Biomanufacturing Training and Education Center (BTEC), North Carolina State University, Raleigh, NC 27695, United States; North Carolina Viral Vector Initiative in Research and Learning, North Carolina State University, Raleigh, NC 27695, United States
| |
Collapse
|
4
|
Scheuermann SE, Goff K, Rowe LA, Beddingfield BJ, Maness NJ. Real-Time Analysis of SARS-CoV-2-Induced Cytolysis Reveals Distinct Variant-Specific Replication Profiles. Viruses 2023; 15:1937. [PMID: 37766343 PMCID: PMC10537736 DOI: 10.3390/v15091937] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2023] [Revised: 08/31/2023] [Accepted: 09/12/2023] [Indexed: 09/29/2023] Open
Abstract
The ability of each new SARS-CoV-2 variant to evade host humoral immunity is the focus of intense research. Each variant may also harbor unique replication capabilities relevant for disease and transmission. Here, we demonstrate a new approach to assessing viral replication kinetics using real-time cell analysis (RTCA). Virus-induced cell death is measured in real time as changes in electrical impedance through cell monolayers while images are acquired at defined intervals via an onboard microscope and camera. Using this system, we quantified replication kinetics of five clinically important viral variants: WA1/2020 (ancestral), Delta, and Omicron subvariants BA.1, BA.4, and BA.5. Multiple measures proved useful in variant replication comparisons, including the elapsed time to, and the slope at, the maximum rate of cell death. Important findings include significantly weaker replication kinetics of BA.1 by all measures, while BA.5 harbored replication kinetics at or near ancestral levels, suggesting evolution to regain replicative capacity, and both an altered profile of cell killing and enhanced fusogenicity of the Delta variant. Together, these data show that RTCA is a robust method to assess replicative capacity of any given SARS-CoV-2 variant rapidly and quantitatively, which may be useful in assessment of newly emerging variants.
Collapse
Affiliation(s)
- Sarah E. Scheuermann
- Division of Microbiology, Tulane National Primate Research Center, Covington, LA 70433, USA; (S.E.S.); (K.G.); (L.A.R.)
| | - Kelly Goff
- Division of Microbiology, Tulane National Primate Research Center, Covington, LA 70433, USA; (S.E.S.); (K.G.); (L.A.R.)
| | - Lori A. Rowe
- Division of Microbiology, Tulane National Primate Research Center, Covington, LA 70433, USA; (S.E.S.); (K.G.); (L.A.R.)
| | - Brandon J. Beddingfield
- Division of Microbiology, Tulane National Primate Research Center, Covington, LA 70433, USA; (S.E.S.); (K.G.); (L.A.R.)
- Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, LA 70112, USA
| | - Nicholas J. Maness
- Division of Microbiology, Tulane National Primate Research Center, Covington, LA 70433, USA; (S.E.S.); (K.G.); (L.A.R.)
- Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, LA 70112, USA
| |
Collapse
|
5
|
Karaoğlu Ö, Serhatlı M, Pelvan E, Karadeniz B, Demirtas I, Çakırca G, Sipahix H, Özhan Y, Karapınar G, Charehsaz M, Aydın A, Yesilada E, Alasalvar C. Chewable tablet with herbal extracts and propolis arrests Wuhan and Omicron variants of SARS-CoV-2 virus. J Funct Foods 2023; 105:105544. [PMID: 37155488 PMCID: PMC10113600 DOI: 10.1016/j.jff.2023.105544] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2023] [Revised: 03/23/2023] [Accepted: 04/14/2023] [Indexed: 05/10/2023] Open
Abstract
Prevention of COVID-19 is of paramount importance for public health. Some natural extracts might have the potential to suppress COVID-19 infection. Therefore, this study aimed to design a standardised, efficient, and safe chewable tablet formulation (with propolis and three herbal extracts) for possible prevention against two variants (Wuhan B.1.36 and Omicron BA.1.1) of SARS-CoV-2 virus and other viral infections. Green tea, bilberry, dried pomegranate peel, and propolis extracts were selected for this purpose. Cytotoxicity and antiviral activity of each component, as well as the developed chewable tablet, were examined against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus using Vero E6 cells with the xCELLigence real-time cell analyser-multiple plates system. Anti-inflammatory and analgesic activities, as well as mutagenicity and anti-mutagenicity of the chewable tablet were also analysed. Compared to the control, it was observed that the chewable tablet at concentrations of 110 and 55 µg/mL had antiviral activity rates of 101% and 81%, respectively, for the Wuhan variant and 112% and 35%, respectively, for the Omicron variant. The combination of herbal extracts with propolis extract were synergically more effective (∼7-fold higher) than that of individual extract. The present work suggests that a combination of herbal extracts with propolis at suitable concentrations can effectively be used as a food supplement for the prevention of both variants of the SARS-CoV-2 virus in the oral cavity (the first entry point of the SARS-CoV-2 virus).
Collapse
Affiliation(s)
- Öznur Karaoğlu
- Life Sciences, TÜBİTAK Marmara Research Center, Gebze-Kocaeli, Turkey
| | - Müge Serhatlı
- Life Sciences, TÜBİTAK Marmara Research Center, Gebze-Kocaeli, Turkey
| | - Ebru Pelvan
- Life Sciences, TÜBİTAK Marmara Research Center, Gebze-Kocaeli, Turkey
| | - Bülent Karadeniz
- Life Sciences, TÜBİTAK Marmara Research Center, Gebze-Kocaeli, Turkey
| | - Ilknur Demirtas
- Life Sciences, TÜBİTAK Marmara Research Center, Gebze-Kocaeli, Turkey
| | - Gamze Çakırca
- Life Sciences, TÜBİTAK Marmara Research Center, Gebze-Kocaeli, Turkey
- Department of Molecular Biology and Genetics, Faculty of Science, Gebze Technical University, Gebze-Kocaeli, Turkey
| | - Hande Sipahix
- Department of Toxicology, Faculty of Pharmacy, Yeditepe University, Ataşehir-İstanbul, Turkey
| | - Yağmur Özhan
- Department of Toxicology, Faculty of Pharmacy, Yeditepe University, Ataşehir-İstanbul, Turkey
| | - Gözdem Karapınar
- Department of Toxicology, Faculty of Pharmacy, Yeditepe University, Ataşehir-İstanbul, Turkey
| | - Mohammad Charehsaz
- Department of Toxicology, Faculty of Pharmacy, Yeditepe University, Ataşehir-İstanbul, Turkey
| | - Ahmet Aydın
- Department of Toxicology, Faculty of Pharmacy, Yeditepe University, Ataşehir-İstanbul, Turkey
| | - Erdem Yesilada
- Department of Pharmacognosy, Faculty of Pharmacy, Yeditepe University, Ataşehir-İstanbul, Turkey
| | | |
Collapse
|
6
|
U5 snRNP Core Proteins Are Key Components of the Defense Response against Viral Infection through Their Roles in Programmed Cell Death and Interferon Induction. Viruses 2022; 14:v14122710. [PMID: 36560714 PMCID: PMC9785106 DOI: 10.3390/v14122710] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2022] [Revised: 11/25/2022] [Accepted: 12/01/2022] [Indexed: 12/11/2022] Open
Abstract
The spliceosome is a massive ribonucleoprotein structure composed of five small nuclear ribonucleoprotein (snRNP) complexes that catalyze the removal of introns from pre-mature RNA during constitutive and alternative splicing. EFTUD2, PRPF8, and SNRNP200 are core components of the U5 snRNP, which is crucial for spliceosome function as it coordinates and performs the last steps of the splicing reaction. Several studies have demonstrated U5 snRNP proteins as targeted during viral infection, with a limited understanding of their involvement in virus-host interactions. In the present study, we deciphered the respective impact of EFTUD2, PRPF8, and SNRNP200 on viral replication using mammalian reovirus as a model. Using a combination of RNA silencing, real-time cell analysis, cell death and viral replication assays, we discovered distinct and partially overlapping novel roles for EFTUD2, PRPF8, and SNRNP200 in cell survival, apoptosis, necroptosis, and the induction of the interferon response pathway. For instance, we demonstrated that EFTUD2 and SNRNP200 are required for both apoptosis and necroptosis, whereas EFTUD2 and PRPF8 are required for optimal interferon response against viral infection. Moreover, we demonstrated that EFTUD2 restricts viral replication, both in a single cycle and multiple cycles of viral replication. Altogether, these results establish U5 snRNP core components as key elements of the cellular antiviral response.
Collapse
|
7
|
Yildiz Pekoz A, Akbal Dagistan O, Fael H, Culha M, Erturk A, Basarir NS, Sahin G, Serhatli M, Cakirca G, Tekin S, Sen LS, Sevim M, Mulazimoglu Durmusoglu L, Yegen BC. Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment: in vitro characterization, stability, in vitro cytotoxicity, and antiviral activity using real time cell analysis. Drug Deliv 2022; 29:2846-2854. [PMID: 36062490 PMCID: PMC9448368 DOI: 10.1080/10717544.2022.2118398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
Favipiravir, an RNA-dependent RNA polymerase (RdRp) inhibitor, is used to treat patients infected with influenza virus and most recently with SARS-CoV-2. However, poor accumulation of favipiravir in lung tissue following oral administration has required an alternative method of administration that directly targets the lungs. In this study, an inhalation solution of favipiravir at a concentration of 2 mg mL-1 was developed and characterized for the first time. The chemical stability of inhaled favipiravir solution in two different media, phosphate buffer saline (PBS) and normal saline (NS), was investigated under different conditions: 5 ± 3 °C, 25 ± 2 °C/60% RH ± 5% RH, and 40 ± 2 °C/75% RH ± 5% RH; in addition to constant light exposure. As a result, favipiravir solution in PBS revealed superior stability over 12 months at 5 ± 3 °C. Antiviral activity of favipiravir was assessed at the concentrations between 0.25 and 3 mg mL-1 with real time cell analyzer on Vero-E6 that were infected with SARS-CoV-2/B.1.36. The optimum concentration was found to be 2 mg mL-1, where minimum toxicity and sufficient antiviral activity was observed. Furthermore, cell viability assay against Calu-3 lung epithelial cells confirmed the biocompatibility of favipiravir at concentrations up to 50 μM (7.855 mg mL-1). The in vitro aerodynamic profiles of the developed inhaled favipiravir formulation, when delivered with soft-mist inhaler indicated good lung targeting properties. These results suggest that favipiravir solution prepared with PBS could be considered as a suitable and promising inhalation formulation for pulmonary delivery in the treatment of patients with COVID-19.
Collapse
Affiliation(s)
- Ayca Yildiz Pekoz
- Faculty of Pharmacy, Department of Pharmaceutical Technology, Istanbul University, Istanbul, Türkiye
| | - Ozlem Akbal Dagistan
- Faculty of Pharmacy, Department of Pharmaceutical Technology, Istanbul University, Istanbul, Türkiye
| | - Hanan Fael
- Faculty of Pharmacy, Department of Pharmaceutical Technology, Istanbul University, Istanbul, Türkiye
| | - Meltem Culha
- Faculty of Pharmacy, Department of Pharmaceutical Technology, Istanbul University, Istanbul, Türkiye
| | - Aybige Erturk
- Faculty of Pharmacy, Department of Pharmaceutical Technology, Istanbul University, Istanbul, Türkiye.,Faculty of Pharmacy, Department of Pharmaceutical Technology, Istinye University, Istanbul, Türkiye
| | - Nur Sena Basarir
- Faculty of Pharmacy, Department of Pharmaceutical Technology, Istanbul University, Istanbul, Türkiye
| | - Gokben Sahin
- Faculty of Pharmacy, Department of Pharmaceutical Technology, Trakya University, Istanbul, Türkiye
| | - Muge Serhatli
- Medical Biotechnology (Marmara Research Center (MRC)), TUBITAK Marmara Research Center-MRC, Life Sciences, Kocaeli, Türkiye
| | - Gamze Cakirca
- Medical Biotechnology (Marmara Research Center (MRC)), TUBITAK Marmara Research Center-MRC, Life Sciences, Kocaeli, Türkiye.,Molecular Biology and Genetics, Institute of Natural and Applied Sciences, Gebze Technical University, Kocaeli, Türkiye
| | - Saban Tekin
- Medical Biotechnology (Marmara Research Center (MRC)), TUBITAK Marmara Research Center-MRC, Life Sciences, Kocaeli, Türkiye.,Hamidiye Faculty of Medicine, Department of Basic Medical Sciences, Medical Biology, University of Health Sciences, Istanbul, Türkiye
| | - Leyla Semiha Sen
- School of Medicine, Basic Medical Sciences, Department of Physiology, Marmara University, Istanbul, Türkiye
| | - Mustafa Sevim
- School of Medicine, Basic Medical Sciences, Department of Physiology, Marmara University, Istanbul, Türkiye
| | | | - Berrak C Yegen
- School of Medicine, Basic Medical Sciences, Department of Physiology, Marmara University, Istanbul, Türkiye
| |
Collapse
|
8
|
Pelvan E, Serhatlı M, Karaoğlu Ö, Karadeniz B, Pembeci Kodolbaş C, Aslı Öncü N, Çakırca G, Damarlı E, Başdoğan G, Mergen Duymaz G, Emir Akyıldız İ, Düz G, Acar S, Özhan Y, Sipahi H, Charehsaz M, Aydın A, Yesilada E, Alasalvar C. Development of propolis and essential oils containing oral/throat spray formulation against SARS-CoV-2 infection. J Funct Foods 2022; 97:105225. [PMID: 35996534 PMCID: PMC9385731 DOI: 10.1016/j.jff.2022.105225] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2022] [Revised: 08/10/2022] [Accepted: 08/12/2022] [Indexed: 12/05/2022] Open
Abstract
A broad range of evidence has confirmed that natural products and essential oils might have the potential to suppress COVID-19 infection. Therefore, this study aimed to develop an oral/throat spray formulation for prophylactic use in the oral cavity or help treatment modalities. Based on a reference survey, several essential oils, a cold-pressed oil, and propolis were selected, and cytotoxicity and antiviral activity of each component and the developed spray formulation were examined against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection using Vero E6 cells. Anti-inflammatory, antimicrobial, and analgesic activities as well as mutagenicity and anti-mutagenicity of the formulation were analysed. Forty-three phenolics were identified in both propolis extract and oral/throat spray. The spray with 1:640-fold dilution provided the highest efficacy and the cytopathic effect was delayed for 54 h at this dilution, and the antiviral activity rate was 85.3%. A combination of natural products with essential oils at the right concentrations can be used as a supplement for the prevention of SARS-CoV-2 infection.
Collapse
Affiliation(s)
- Ebru Pelvan
- Life Sciences, TÜBİTAK Marmara Research Center, Gebze-Kocaeli, Turkey
| | - Müge Serhatlı
- Life Sciences, TÜBİTAK Marmara Research Center, Gebze-Kocaeli, Turkey
| | - Öznur Karaoğlu
- Life Sciences, TÜBİTAK Marmara Research Center, Gebze-Kocaeli, Turkey
| | - Bülent Karadeniz
- Life Sciences, TÜBİTAK Marmara Research Center, Gebze-Kocaeli, Turkey
| | | | - Neşe Aslı Öncü
- Life Sciences, TÜBİTAK Marmara Research Center, Gebze-Kocaeli, Turkey
| | - Gamze Çakırca
- Life Sciences, TÜBİTAK Marmara Research Center, Gebze-Kocaeli, Turkey,Department of Molecular Biology and Genetics, Faculty of Science, Gebze Technical University, Gebze-Kocaeli, Turkey
| | - Emel Damarlı
- Altıparmak Gıda San. & Tic. A.Ş, Çekmeköy-Istanbul, Turkey
| | - Günay Başdoğan
- Altıparmak Gıda San. & Tic. A.Ş, Çekmeköy-Istanbul, Turkey
| | | | | | - Gamze Düz
- Altıparmak Gıda San. & Tic. A.Ş, Çekmeköy-Istanbul, Turkey
| | - Sezer Acar
- Altıparmak Gıda San. & Tic. A.Ş, Çekmeköy-Istanbul, Turkey
| | - Yağmur Özhan
- Department of Toxicology, Faculty of Pharmacy, Yeditepe University, Ataşehir-Istanbul, Turkey
| | - Hande Sipahi
- Department of Toxicology, Faculty of Pharmacy, Yeditepe University, Ataşehir-Istanbul, Turkey
| | - Mohammad Charehsaz
- Department of Toxicology, Faculty of Pharmacy, Yeditepe University, Ataşehir-Istanbul, Turkey
| | - Ahmet Aydın
- Department of Toxicology, Faculty of Pharmacy, Yeditepe University, Ataşehir-Istanbul, Turkey
| | - Erdem Yesilada
- Department of Pharmacognosy, Faculty of Pharmacy, Yeditepe University, Ataşehir-Istanbul, Turkey
| | - Cesarettin Alasalvar
- Life Sciences, TÜBİTAK Marmara Research Center, Gebze-Kocaeli, Turkey,Corresponding author
| |
Collapse
|
9
|
Oeyen M, Meyen E, Doijen J, Schols D. In-Depth Characterization of Zika Virus Inhibitors Using Cell-Based Electrical Impedance. Microbiol Spectr 2022; 10:e0049122. [PMID: 35862960 PMCID: PMC9431523 DOI: 10.1128/spectrum.00491-22] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2022] [Accepted: 06/20/2022] [Indexed: 11/30/2022] Open
Abstract
In this study, we use electric cell-substrate impedance sensing (ECIS), an established cell-based electrical impedance (CEI) technology, to decipher the kinetic cytopathic effect (CPE) induced by Zika virus (ZIKV) in susceptible human A549 lung epithelial cells and to evaluate several classes of compounds with reported antiviral activity (two entry inhibitors and two replication inhibitors). To validate the assay, we compare the results with those obtained with more traditional in vitro methods based on cell viability and viral yield readouts. We demonstrate that CEI can detect viral infection in a sensitive manner and can be used to determine antiviral potency. Moreover, CEI has multiple benefits compared to conventional assays: the technique is less laborious and better at visualizing the dynamic antiviral activity profile of the compounds, while also it has the ability to determine interesting time points that can be selected as endpoints in assays without continuous readout. We describe several parameters to characterize the compounds' cytotoxicity and their antiviral activity profile. In addition, the CEI patterns provide valuable additional information about the presumed mechanism of action of these compounds. Finally, as a proof of concept, we used CEI to evaluate the antiviral activity of a small series of compounds, for which we demonstrate that the sulfonated polymer PRO2000 inhibits ZIKV with a response profile representative for a viral entry inhibitor. Overall, we demonstrate for the first time that CEI is a powerful technology to evaluate and characterize compounds against ZIKV replication in a real-time, label-free, and noninvasive manner. IMPORTANCE Zika virus can cause serious disease in humans. Unfortunately, no antiviral drugs are available to treat infection. Here, we use an impedance-based method to continuously monitor virus infection in-and damage to-human cells. We can determine the Zika viral dose with this technique and also evaluate whether antiviral compounds protect the cells from damage caused by virus replication. We also show that this technique can be used to further unravel the characteristics of these compounds, such as their toxicity to the cells, and that it might even give further insight in their mechanism of antiviral action. Finally, we also find a novel Zika virus inhibitor, PRO2000. Overall, in this study, we use the impedance technology to-for the first time-evaluate compounds with anti-Zika virus properties, and therefore it can add valuable information in the further search for antiviral drugs.
Collapse
Affiliation(s)
- Merel Oeyen
- Katholieke Universiteit Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Leuven, Belgium
| | - Eef Meyen
- Katholieke Universiteit Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Leuven, Belgium
| | - Jordi Doijen
- Katholieke Universiteit Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Leuven, Belgium
| | - Dominique Schols
- Katholieke Universiteit Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Leuven, Belgium
| |
Collapse
|
10
|
Decataldo F, Giovannini C, Grumiro L, Marino MM, Faccin F, Brandolini M, Dirani G, Taddei F, Lelli D, Tessarolo M, Calienni M, Cacciotto C, De Pascali AM, Lavazza A, Fraboni B, Sambri V, Scagliarini A. Organic Electrochemical Transistors as Versatile Tool for Real-Time and Automatized Viral Cytopathic Effect Evaluation. Viruses 2022; 14:1155. [PMID: 35746627 PMCID: PMC9227436 DOI: 10.3390/v14061155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2022] [Revised: 05/24/2022] [Accepted: 05/25/2022] [Indexed: 02/01/2023] Open
Abstract
In-vitro viral studies are still fundamental for biomedical research since studying the virus kinetics on cells is crucial for the determination of the biological properties of viruses and for screening the inhibitors of infections. Moreover, testing potential viral contaminants is often mandatory for safety evaluation. Nowadays, viral cytopathic effects are mainly evaluated through end-point assays requiring dye-staining combined with optical evaluation. Recently, optical-based automatized equipment has been marketed, aimed at the real-time screening of cell-layer status and obtaining further insights, which are unavailable with end-point assays. However, these technologies present two huge limitations, namely, high costs and the possibility to study only cytopathic viruses, whose effects lead to plaque formation and layer disruption. Here, we employed poly(3,4-ethylenedioxythiophene):poly(styrene sulfonate) (Pedot:Pss) organic electrochemical transistors (OECTs) for the real-time, electrical monitoring of the infection of cytolytic viruses, i.e., encephalomyocarditis virus (EMCV), and non-cytolytic viruses, i.e., bovine coronavirus (B-CoV), on cells. OECT data on EMCV were validated using a commercially-available optical-based technology, which, however, failed in the B-CoV titration analysis, as expected. The OECTs proved to be reliable, fast, and versatile devices for viral infection monitoring, which could be scaled up at low cost, reducing the operator workload and speeding up in-vitro assays in the biomedical research field.
Collapse
Affiliation(s)
- Francesco Decataldo
- Department of Physics and Astronomy, Alma Mater Studiorum, University of Bologna, 40127 Bologna, Italy; (F.D.); (M.T.); (M.C.)
| | - Catia Giovannini
- Department of Experimental, Diagnostic and Specialty Medicine—DIMES, Universtity of Bologna, 40138 Bologna, Italy; (C.G.); (C.C.); (A.M.D.P.); (A.S.)
- Center for Applied Biomedical Research (CRBA), S. Orsola-Malpighi University Hospital, 40138 Bologna, Italy
| | - Laura Grumiro
- Unit of Microbiology, The Great Romagna Hub Laboratory, 47522 Pievesestina, Italy; (L.G.); (M.M.M.); (M.B.); (G.D.); (F.T.)
| | - Maria Michela Marino
- Unit of Microbiology, The Great Romagna Hub Laboratory, 47522 Pievesestina, Italy; (L.G.); (M.M.M.); (M.B.); (G.D.); (F.T.)
| | - Francesca Faccin
- Experimental Zooprofilactic Institute of Lombardy and Emilia Romagna“Bruno Ubertini” (IZSLER), 25124 Brescia, Italy; (F.F.); (D.L.); (A.L.)
| | - Martina Brandolini
- Unit of Microbiology, The Great Romagna Hub Laboratory, 47522 Pievesestina, Italy; (L.G.); (M.M.M.); (M.B.); (G.D.); (F.T.)
| | - Giorgio Dirani
- Unit of Microbiology, The Great Romagna Hub Laboratory, 47522 Pievesestina, Italy; (L.G.); (M.M.M.); (M.B.); (G.D.); (F.T.)
| | - Francesca Taddei
- Unit of Microbiology, The Great Romagna Hub Laboratory, 47522 Pievesestina, Italy; (L.G.); (M.M.M.); (M.B.); (G.D.); (F.T.)
| | - Davide Lelli
- Experimental Zooprofilactic Institute of Lombardy and Emilia Romagna“Bruno Ubertini” (IZSLER), 25124 Brescia, Italy; (F.F.); (D.L.); (A.L.)
| | - Marta Tessarolo
- Department of Physics and Astronomy, Alma Mater Studiorum, University of Bologna, 40127 Bologna, Italy; (F.D.); (M.T.); (M.C.)
| | - Maria Calienni
- Department of Physics and Astronomy, Alma Mater Studiorum, University of Bologna, 40127 Bologna, Italy; (F.D.); (M.T.); (M.C.)
| | - Carla Cacciotto
- Department of Experimental, Diagnostic and Specialty Medicine—DIMES, Universtity of Bologna, 40138 Bologna, Italy; (C.G.); (C.C.); (A.M.D.P.); (A.S.)
| | - Alessandra Mistral De Pascali
- Department of Experimental, Diagnostic and Specialty Medicine—DIMES, Universtity of Bologna, 40138 Bologna, Italy; (C.G.); (C.C.); (A.M.D.P.); (A.S.)
| | - Antonio Lavazza
- Experimental Zooprofilactic Institute of Lombardy and Emilia Romagna“Bruno Ubertini” (IZSLER), 25124 Brescia, Italy; (F.F.); (D.L.); (A.L.)
| | - Beatrice Fraboni
- Department of Physics and Astronomy, Alma Mater Studiorum, University of Bologna, 40127 Bologna, Italy; (F.D.); (M.T.); (M.C.)
| | - Vittorio Sambri
- Department of Experimental, Diagnostic and Specialty Medicine—DIMES, Universtity of Bologna, 40138 Bologna, Italy; (C.G.); (C.C.); (A.M.D.P.); (A.S.)
- Unit of Microbiology, The Great Romagna Hub Laboratory, 47522 Pievesestina, Italy; (L.G.); (M.M.M.); (M.B.); (G.D.); (F.T.)
| | - Alessandra Scagliarini
- Department of Experimental, Diagnostic and Specialty Medicine—DIMES, Universtity of Bologna, 40138 Bologna, Italy; (C.G.); (C.C.); (A.M.D.P.); (A.S.)
| |
Collapse
|
11
|
Brass O, Claudy P, Grenier E. Reliable Stability Prediction to Manage Research or Marketed Vaccines and Pharmaceutical Products. “Avoid any doubt for the end-user of vaccine compliance at time of administration”. Int J Pharm 2022; 618:121604. [DOI: 10.1016/j.ijpharm.2022.121604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2021] [Revised: 02/10/2022] [Accepted: 02/16/2022] [Indexed: 11/16/2022]
|
12
|
Durdagi S, Avsar T, Orhan MD, Serhatli M, Balcioglu BK, Ozturk HU, Kayabolen A, Cetin Y, Aydinlik S, Bagci-Onder T, Tekin S, Demirci H, Guzel M, Akdemir A, Calis S, Oktay L, Tolu I, Butun YE, Erdemoglu E, Olkan A, Tokay N, Işık Ş, Ozcan A, Acar E, Buyukkilic S, Yumak Y. The neutralization effect of montelukaston SARS-CoV-2 is shown by multiscale in silicosimulations and combined in vitro studies. Mol Ther 2021; 30:963-974. [PMID: 34678509 PMCID: PMC8524809 DOI: 10.1016/j.ymthe.2021.10.014] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2021] [Revised: 08/31/2021] [Accepted: 10/15/2021] [Indexed: 12/22/2022] Open
Abstract
Small molecule inhibitors have previously been investigated in different studies as possible therapeutics in the treatment of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). In the current drug repurposing study, we identified the leukotriene (D4) receptor antagonist montelukast as a novel agent that simultaneously targets two important drug targets of SARS-CoV-2. We initially demonstrated the dual inhibition profile of montelukast through multiscale molecular modeling studies. Next, we characterized its effect on both targets by different in vitro experiments including the enzyme (main protease) inhibition-based assay, surface plasmon resonance (SPR) spectroscopy, pseudovirus neutralization on HEK293T/hACE2+TMPRSS2, and virus neutralization assay using xCELLigence MP real-time cell analyzer. Our integrated in silico and in vitro results confirmed the dual potential effect of montelukast both on the main protease enzyme inhibition and virus entry into the host cell (spike/ACE2). The virus neutralization assay results showed that SARS-CoV-2 virus activity was delayed with montelukast for 20 h on the infected cells. The rapid use of new small molecules in the pandemic is very important today. Montelukast, whose pharmacokinetic and pharmacodynamic properties are very well characterized and has been widely used in the treatment of asthma since 1998, should urgently be completed in clinical phase studies and, if its effect is proved in clinical phase studies, it should be used against coronavirus disease 2019 (COVID-19).
Collapse
Affiliation(s)
- Serdar Durdagi
- Department of Biophysics, Computational Biology and Molecular Simulations Laboratory, School of Medicine, Bahçeşehir University, Istanbul, Turkey.
| | - Timucin Avsar
- Department of Medical Biology, School of Medicine, Bahçeşehir University, Istanbul, Turkey
| | - Muge Didem Orhan
- Department of Medical Biology, School of Medicine, Bahçeşehir University, Istanbul, Turkey
| | - Muge Serhatli
- The Scientific and Technological Research Council of Turkey (TÜBİTAK) Marmara Research Center (MAM), Genetic Engineering and Biotechnology Institute, 41470 Gebze, Kocaeli
| | - Bertan Koray Balcioglu
- The Scientific and Technological Research Council of Turkey (TÜBİTAK) Marmara Research Center (MAM), Genetic Engineering and Biotechnology Institute, 41470 Gebze, Kocaeli
| | - Hasan Umit Ozturk
- The Scientific and Technological Research Council of Turkey (TÜBİTAK) Marmara Research Center (MAM), Genetic Engineering and Biotechnology Institute, 41470 Gebze, Kocaeli
| | - Alisan Kayabolen
- Brain Cancer Research and Therapy Laboratory, Koç University School of Medicine, 34450 Istanbul, Turkey
| | - Yuksel Cetin
- The Scientific and Technological Research Council of Turkey (TÜBİTAK) Marmara Research Center (MAM), Genetic Engineering and Biotechnology Institute, 41470 Gebze, Kocaeli
| | - Seyma Aydinlik
- The Scientific and Technological Research Council of Turkey (TÜBİTAK) Marmara Research Center (MAM), Genetic Engineering and Biotechnology Institute, 41470 Gebze, Kocaeli
| | - Tugba Bagci-Onder
- Brain Cancer Research and Therapy Laboratory, Koç University School of Medicine, 34450 Istanbul, Turkey; Koç University Research Center for Translational Medicine, 34450 Istanbul, Turkey
| | - Saban Tekin
- The Scientific and Technological Research Council of Turkey (TÜBİTAK) Marmara Research Center (MAM), Genetic Engineering and Biotechnology Institute, 41470 Gebze, Kocaeli; Department of Basic Sciences, Division of Medical Biology, Faculty of Medicine, University of Health Sciences, Istanbul, Turkey
| | - Hasan Demirci
- Department of Molecular Biology and Genetics, Koç University, 34450 Istanbul, Turkey
| | - Mustafa Guzel
- Department of Medical Pharmacology, International School of Medicine, Istanbul Medipol University, Istanbul, Turkey
| | - Atilla Akdemir
- Department of Pharmacology, Computer-aided Drug Discovery Laboratory, Faculty of Pharmacy, Bezmialem Vakif University, Istanbul, Turkey
| | - Seyma Calis
- Department of Medical Biology, School of Medicine, Bahçeşehir University, Istanbul, Turkey; Department of Molecular Biology-Genetics and Biotechnology, Istanbul Technical University, 34485 Istanbul, Turkey
| | - Lalehan Oktay
- Department of Biophysics, Computational Biology and Molecular Simulations Laboratory, School of Medicine, Bahçeşehir University, Istanbul, Turkey
| | - Ilayda Tolu
- Department of Biophysics, Computational Biology and Molecular Simulations Laboratory, School of Medicine, Bahçeşehir University, Istanbul, Turkey
| | - Yasar Enes Butun
- Department of Medical Pharmacology, International School of Medicine, Istanbul Medipol University, Istanbul, Turkey
| | - Ece Erdemoglu
- Department of Biophysics, Computational Biology and Molecular Simulations Laboratory, School of Medicine, Bahçeşehir University, Istanbul, Turkey; Faculty of Medicine, Mersin University, Mersin, Turkey
| | - Alpsu Olkan
- Department of Biophysics, Computational Biology and Molecular Simulations Laboratory, School of Medicine, Bahçeşehir University, Istanbul, Turkey
| | - Nurettin Tokay
- The Scientific and Technological Research Council of Turkey (TÜBİTAK) Marmara Research Center (MAM), Genetic Engineering and Biotechnology Institute, 41470 Gebze, Kocaeli
| | - Şeyma Işık
- The Scientific and Technological Research Council of Turkey (TÜBİTAK) Marmara Research Center (MAM), Genetic Engineering and Biotechnology Institute, 41470 Gebze, Kocaeli
| | - Aysenur Ozcan
- Department of Biophysics, Computational Biology and Molecular Simulations Laboratory, School of Medicine, Bahçeşehir University, Istanbul, Turkey; Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey
| | - Elif Acar
- Department of Biophysics, Computational Biology and Molecular Simulations Laboratory, School of Medicine, Bahçeşehir University, Istanbul, Turkey; Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey
| | - Sehriban Buyukkilic
- Department of Biophysics, Computational Biology and Molecular Simulations Laboratory, School of Medicine, Bahçeşehir University, Istanbul, Turkey; Faculty of Science, Necmettin Erbakan University, Konya, Turkey
| | - Yesim Yumak
- Department of Biophysics, Computational Biology and Molecular Simulations Laboratory, School of Medicine, Bahçeşehir University, Istanbul, Turkey; Faculty of Science and Letters, Tokat Gaziosmanpaşa University, Tokat, Turkey
| |
Collapse
|
13
|
Purtscher M, Rothbauer M, Kratz SRA, Bailey A, Lieberzeit P, Ertl P. A microfluidic impedance-based extended infectivity assay: combining retroviral amplification and cytopathic effect monitoring on a single lab-on-a-chip platform. LAB ON A CHIP 2021; 21:1364-1372. [PMID: 33566877 DOI: 10.1039/d0lc01056a] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Detection, quantification and monitoring of virus - host cell interactions are of great importance when evaluating the safety of pharmaceutical products. With the wide usage of viral based vector systems in combination with mammalian cell lines for the production of biopharmaceuticals, the presence of replication competent viral particles needs to be avoided and potential hazards carefully assessed. Consequently, regulatory agencies recommend viral clearance studies using plaque assays or TCID50 assays to evaluate the efficiency of the production process in removing viruses. While plaque assays provide reliable information on the presence of viral contaminations, they are still tedious to perform and can take up to two weeks to finish. To overcome some of these limitations, we have automated, miniaturized and integrated the dual cell culture bioassay into a common lab-on-a-chip platform containing embedded electrical sensor arrays to enrich and detect infectious viruses. Results of our microfluidic single step assay show that a significant reduction in assay time down to 3 to 4 days can be achieved using simultaneous cell-based viral amplification, release and detection of cytopathic effects in a target cell line. We further demonstrate the enhancing effect of continuous fluid flow on infection of PG-4 reporter cells by newly formed and highly active virions by M. dunni cells, thus pointing to the importance of physical relevant viral-cell interactions.
Collapse
Affiliation(s)
- Michaela Purtscher
- University of Applied Sciences FH Technikum Wien, Höchstädtplatz 6, 1200 Vienna, Austria
| | | | | | | | | | | |
Collapse
|
14
|
Bernardo L, Corallo L, Caterini J, Su J, Gisonni-Lex L, Gajewska B. Application of xCELLigence real-time cell analysis to the microplate assay for pertussis toxin induced clustering in CHO cells. PLoS One 2021; 16:e0248491. [PMID: 33720984 PMCID: PMC7959359 DOI: 10.1371/journal.pone.0248491] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2020] [Accepted: 02/27/2021] [Indexed: 02/06/2023] Open
Abstract
The microplate assay with Chinese Hamster Ovary (CHO) cells is currently used as a safety test to monitor the residual pertussis toxin (PT) amount in acellular pertussis antigens prior to vaccine formulation. The assay is based on the findings that the exposure of CHO cells to PT results in a concentration-dependent clustering response which can be used to estimate the amount of PT in a sample preparation. A major challenge with the current CHO cell assay methodology is that scoring of PT-induced clustering is dependent on subjective operator visual assessment using light microscopy. In this work, we have explored the feasibility of replacing the microscopy readout for the CHO cell assay with the xCELLigence Real-Time Cell Analysis system (ACEA BioSciences, a part of Agilent). The xCELLigence equipment is designed to monitor cell adhesion and growth. The electrical impedance generated from cell attachment and proliferation is quantified via gold electrodes at the bottom of the cell culture plate wells, which is then translated into a unitless readout called cell index. Results showed significant decrease in the cell index readouts of CHO cells exposed to PT compared to the cell index of unexposed CHO cells. Similar endpoint concentrations were obtained when the PT reference standard was titrated with either xCELLigence or microscopy. Testing genetically detoxified pertussis samples unspiked or spiked with PT further supported the sensitivity and reproducibility of the xCELLigence assay in comparison with the conventional microscopy assay. In conclusion, the xCELLigence RTCA system offers an alternative automated and higher throughput method for evaluating PT-induced clustering in CHO cells.
Collapse
Affiliation(s)
- Lidice Bernardo
- Department of Analytical Sciences, Sanofi Pasteur, Toronto, ON, Canada
- * E-mail:
| | - Lucas Corallo
- Department of Analytical Sciences, Sanofi Pasteur, Toronto, ON, Canada
| | - Judy Caterini
- Department of Analytical Sciences, Sanofi Pasteur, Toronto, ON, Canada
| | - Jin Su
- Department of Analytical Sciences, Sanofi Pasteur, Toronto, ON, Canada
| | - Lucy Gisonni-Lex
- Department of Analytical Sciences, Sanofi Pasteur, Toronto, ON, Canada
| | - Beata Gajewska
- Department of Analytical Sciences, Sanofi Pasteur, Toronto, ON, Canada
| |
Collapse
|
15
|
Moetlhoa B, Naicker L, Hayeshi R, Grobler A, Mokoena NB, Mawadza C. Application of a real-time cell analysis system in the process development and quantification of Rift Valley fever virus clone 13. Access Microbiol 2021; 3:000191. [PMID: 34151150 PMCID: PMC8209705 DOI: 10.1099/acmi.0.000191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2020] [Accepted: 11/17/2020] [Indexed: 11/18/2022] Open
Abstract
Conventional cell-culture viral quantification methods, namely viral plaque and 50 % tissue culture infective dose assays, are time-consuming, subjective and are not suitable for routine testing. The viral plaque formation assay is the main method utilized for Rift Valley fever virus (RVFV) clone 13 quantification. The RVFV is a mosquito-borne RNA Phlebovirus belonging to the family Bunyaviridae. The virus comprises a single serotype and causes the zoonotic Rift Valley fever disease. The real-time cell analysis (RTCA) system has been developed for the monitoring of cell growth, cell adhesion, cell viability and mortality using electronic impedance technology. In this study, Vero cell growth kinetics and RVFV clone 13 replication kinetics were investigated in a roller bottle and RTCA systems. In roller bottles, Vero cell growth was measured by cell counts through trypan blue staining, whilst impedance expressed as the cell index (CI) was used for Vero growth measurement in the RTCA system. Similar growth patterns were observed in both roller bottle and RTCA systems. Exponential growth phase was observed between 48 and 100 h, followed by a stationary phase from 100 to 120 h, before cell death was observed. Viral plaque assay quantification of RVFV clone 13 in the roller bottle system and the time required for the CI to decrease 50 % after virus infection (CIT50) in the RTCA system were comparable. The highest RVFV clone 13 titre was obtained at 120 h in both roller bottle and RTCA systems. An increase in time for cytopathic effect (CPE) formation was observed with a decrease in the concentration of the virus used to infect the RTCA plates. A positive correlation was observed between the viral concentration and the time for a CPE and was used to calculate CIT50. A similar correlation was observed between the viral concentration and the time for a CPE in the roller bottle system. This study shows that the RTCA system can be used as an alternative method for conducting cell culture kinetics and viral quantification.
Collapse
Affiliation(s)
- Boitumelo Moetlhoa
- Onderstepoort Biological Products (OBP) SOC Ltd, 100 Old Soutpan Road, Onderstepoort 0110, South Africa
- DST-NWU Preclinical Drug Development Platform (PCDDP), North-West University, Potchefstroom 2520, South Africa
| | - Leeann Naicker
- Onderstepoort Biological Products (OBP) SOC Ltd, 100 Old Soutpan Road, Onderstepoort 0110, South Africa
| | - Rose Hayeshi
- DST-NWU Preclinical Drug Development Platform (PCDDP), North-West University, Potchefstroom 2520, South Africa
| | - Anne Grobler
- DST-NWU Preclinical Drug Development Platform (PCDDP), North-West University, Potchefstroom 2520, South Africa
| | - Nobalanda B. Mokoena
- Onderstepoort Biological Products (OBP) SOC Ltd, 100 Old Soutpan Road, Onderstepoort 0110, South Africa
| | - Crispen Mawadza
- Onderstepoort Biological Products (OBP) SOC Ltd, 100 Old Soutpan Road, Onderstepoort 0110, South Africa
| |
Collapse
|
16
|
Integrated pipeline for the accelerated discovery of antiviral antibody therapeutics. Nat Biomed Eng 2020; 4:1030-1043. [PMID: 32747832 PMCID: PMC7655621 DOI: 10.1038/s41551-020-0594-x] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2020] [Accepted: 06/26/2020] [Indexed: 02/06/2023]
Abstract
The emergence and re-emergence of highly virulent viral pathogens with pandemic potential creates an urgent need for the accelerated discovery of antiviral therapeutics. Antiviral human monoclonal antibodies (mAbs) are promising candidates to prevent or treat severe viral diseases, but their long development timeframes limit their rapid deployment and use. Here, we report the development of an integrated sequence of technologies, including single-cell mRNA sequence analysis, bioinformatics, synthetic biology and high-throughput functional analysis, that enabled the rapid discovery of highly potent antiviral human mAbs, whose activity we validated in vivo. In a 78-day study modelling the deployment of a rapid response to an outbreak, we isolated more than 100 human mAbs specific for the Zika virus, assessed their function, identified 29 of those as having broadly neutralizing activity, and verified the therapeutic potency of the lead candidates in mice and non-human primate models of infection via the delivery of an antibody-encoding mRNA formulation and of the respective IgG antibody. The pipeline provides a roadmap for rapid antibody-discovery programs against viral pathogens of global concern.
Collapse
|
17
|
Pickering P, Hugo LE, Devine GJ, Aaskov JG, Liu W. Australian Aedes aegypti mosquitoes are susceptible to infection with a highly divergent and sylvatic strain of dengue virus type 2 but are unlikely to transmit it. Parasit Vectors 2020; 13:240. [PMID: 32393378 PMCID: PMC7212620 DOI: 10.1186/s13071-020-04091-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2019] [Accepted: 04/17/2020] [Indexed: 11/10/2022] Open
Abstract
Background Humans are the primary hosts of dengue viruses (DENV). However, sylvatic cycles of transmission can occur among non-human primates and human encroachment into forested regions can be a source of emergence of new strains such as the highly divergent and sylvatic strain of DENV2, QML22, recovered from a dengue fever patient returning to Australia from Borneo. The objective of the present study was to evaluate the vector competence of Australian Aedes aegypti mosquitoes for this virus. Methods Four- to five-day-old mosquitoes from two strains of Ae. aegypti from Queensland, Australia, were fed a meal of sheep blood containing 108 50% cell culture infectious dose per ml (CCID50/ml) of either QML22 or an epidemic strain of DENV serotype 2 (QML16) isolated from a dengue fever patient in Australia in 2015. Mosquitoes were maintained at 28 °C, 75% relative humidity and sampled 7, 10 and 14 days post-infection (dpi). Live virions in mosquito bodies (abdomen/thorax), legs and wings and saliva expectorates from individual mosquitoes were quantified using a cell culture enzyme-linked immunosorbent assay (CCELISA) to determine infection, dissemination and transmission rates. Results The infection and dissemination rates of the sylvatic DENV2 strain, QML22, were significantly lower than that for QML16. While the titres of virus in the bodies of mosquitoes infected with either of these viruses were similar, titres in legs and wings were significantly lower in mosquitoes infected with QML22 at most time points although they reached similar levels by 14 dpi. QML16 was detected in 16% (n = 25) and 28% (n = 25) of saliva expectorates at 10 and 14 dpi, respectively. In contrast, no virus was detected in the saliva expectorates of QML22 infected mosquitoes. Conclusions Australia urban/peri-urban Ae. aegypti species are susceptible to infection by the sylvatic and highly divergent DENV 2 QML22 but replication of QML22 is attenuated relative to the contemporary strain, QML16. A salivary gland infection or escape barrier may be acting to prevent infection of saliva and would prevent onward transmission of this highly divergent virus in Australia.![]()
Collapse
Affiliation(s)
- Paul Pickering
- Australian Defence Force Malaria and Infectious Disease Institute, Brisbane, Australia
| | - Leon E Hugo
- Queensland Institute of Medical Research-Berghofer Medical Research Institute, Brisbane, Australia
| | - Gregor J Devine
- Queensland Institute of Medical Research-Berghofer Medical Research Institute, Brisbane, Australia
| | - John G Aaskov
- Australian Defence Force Malaria and Infectious Disease Institute, Brisbane, Australia.,Queensland University of Technology, Brisbane, Australia
| | - Wenjun Liu
- Australian Defence Force Malaria and Infectious Disease Institute, Brisbane, Australia.
| |
Collapse
|
18
|
Ayala-Charca G, Munidasa S, Ghafar-Zadeh E, Magerowski S. A high-throughput impedimetric platform for cellular analysis: Design, Implementation and Experimental Results. ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. ANNUAL INTERNATIONAL CONFERENCE 2018; 2018:4261-4264. [PMID: 30441295 DOI: 10.1109/embc.2018.8513396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
A high-throughput impedance spectroscopy measurement system was designed and developed for the purpose of biological analysis. This platform consists of a microchip containing a microelectrode array and a multiplexing interface system. Herein we put forward the proposed platform and demonstrate its functionality by performing impedance analysis using N2a cells and its associated medium. The early experimental results demonstrated the high-through impedimetric system to be a strong basis for future modification and development.
Collapse
|
19
|
Thieulent CJ, Hue ES, Fortier CI, Dallemagne P, Zientara S, Munier-Lehmann H, Hans A, Fortier GD, Pitel PH, Vidalain PO, Pronost SL. Screening and evaluation of antiviral compounds against Equid alpha-herpesviruses using an impedance-based cellular assay. Virology 2018; 526:105-116. [PMID: 30388626 DOI: 10.1016/j.virol.2018.10.013] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2018] [Accepted: 10/14/2018] [Indexed: 01/04/2023]
Abstract
Equid alpha-herpesviruses (EHV) are responsible for different diseases in equine population. EHV-1 causes respiratory diseases, abortions and nervous disorders, EHV-4 causes respiratory diseases and sporadic abortion, while EHV-3 is responsible of equine coital exanthema. In view of the lack of efficacy of vaccines against EHV-1 and EHV-4 and in the absence of vaccines against EHV-3, the use of antiviral treatment is of great interest. In this study, we documented the interest of the Real-Time Cell Analysis (RTCA) technology to monitor the cytopathic effects induced by these viruses on equine dermal cells, and established the efficacy of this method to evaluate the antiviral effect of aciclovir (ACV) and ganciclovir (GCV). In addition, the RTCA technology has also been found appropriate for the high-throughput screening of small molecules against EHV, allowing the identification of spironolactone as a novel antiviral against EHV.
Collapse
Affiliation(s)
- Côme J Thieulent
- LABÉO Frank Duncombe, 14280 Saint-Contest, France; Normandie Univ, UNICAEN, BIOTARGEN EA7450, 14280 Saint-Contest, France
| | - Erika S Hue
- LABÉO Frank Duncombe, 14280 Saint-Contest, France; Normandie Univ, UNICAEN, BIOTARGEN EA7450, 14280 Saint-Contest, France; Normandie Univ, UNICAEN, ImpedanCELL core facility, SF 4206 ICORE, 14280 Saint-Contest, France
| | - Christine I Fortier
- LABÉO Frank Duncombe, 14280 Saint-Contest, France; Normandie Univ, UNICAEN, BIOTARGEN EA7450, 14280 Saint-Contest, France; Normandie Univ, UNICAEN, ImpedanCELL core facility, SF 4206 ICORE, 14280 Saint-Contest, France
| | | | - Stéphan Zientara
- Université Paris-Est, Laboratoire de Santé Animale, ANSES, INRA, ENVA, UMR 1161 Virologie, 94700 Maisons-Alfort, France
| | - Hélène Munier-Lehmann
- Institut Pasteur, Unité de Chimie et Biocatalyse, CNRS UMR 3523, 75015 Paris, France
| | - Aymeric Hans
- ANSES, Laboratoire de pathologie équine de Dozulé, Unité de virologie et parasitologie équine, 14430 Dozulé, France
| | - Guillaume D Fortier
- LABÉO Frank Duncombe, 14280 Saint-Contest, France; Normandie Univ, UNICAEN, BIOTARGEN EA7450, 14280 Saint-Contest, France
| | | | - Pierre-Olivier Vidalain
- Equipe Chimie et Biologie, Modélisation et Immunologie pour la Thérapie (CBMIT), Université Paris Descartes, CNRS UMR 8601, 75006 Paris, France
| | - Stéphane L Pronost
- LABÉO Frank Duncombe, 14280 Saint-Contest, France; Normandie Univ, UNICAEN, BIOTARGEN EA7450, 14280 Saint-Contest, France; Normandie Univ, UNICAEN, ImpedanCELL core facility, SF 4206 ICORE, 14280 Saint-Contest, France.
| |
Collapse
|
20
|
Lebourgeois S, Fraisse A, Hennechart-Collette C, Guillier L, Perelle S, Martin-Latil S. Development of a Real-Time Cell Analysis (RTCA) Method as a Fast and Accurate Method for Detecting Infectious Particles of the Adapted Strain of Hepatitis A Virus. Front Cell Infect Microbiol 2018; 8:335. [PMID: 30319992 PMCID: PMC6167467 DOI: 10.3389/fcimb.2018.00335] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2018] [Accepted: 08/30/2018] [Indexed: 11/26/2022] Open
Abstract
Hepatitis A virus (HAV) is one of the most common agents causing acute liver disease worldwide. HAV has been increasingly reported as the cause of foodborne disease outbreaks. The standard method currently available for detection of the genome of HAV in vulnerable foodstuffs is by RT-qPCR (ISO 15216). Despite its usefulness in the investigation of foodborne viruses, the use of RT-qPCR in food virology has been shown to overestimate the quantity of infectious virus or to highly underestimate the effect of the treatment on virus inactivation. The gold standard methods currently used for evaluating the efficacy of inactivation treatments on the adapted strain of HAV (HM175/18f) are either the plaque assay or the end-point dilution assay (TCID50). However, both assays are labor-intensive and time-consuming. The aim of this study was to evaluate the use of the xCELLigence real-time cell analysis (RTCA) system for detecting the infectivity of the adapted strain of HAV. Kinetics of cell impedance showed that HAV induced a decrease in cell index (CI) correlated with the onset of HAV-induced cell death. In addition, the time to which the HAV-induced CI drop occurred was dependent on the viral concentration. An inverse linear relation could be established over a range of 5 log10 between the concentration of HAV and the time to reach 50% of CI decrease (TCI50), showing that the RTCA assay could be used as a titration method for HAV. In addition, the RTCA-based assay could be performed in less than 6 days instead of 12 to 14 days with the gold standard methods. Therefore, the RTCA-based titration method is a powerful and suitable tool for high-throughput screening of anti-viral treatments. Its usefulness in HAV inactivation studies will improve the assessment of viral risk in food virology, as controlling transmission of viruses through their removal from foodstuffs is also an important challenge in reducing the burden of viral foodborne illnesses.
Collapse
Affiliation(s)
- Samuel Lebourgeois
- Laboratory for Food Safety, Université Paris Est, ANSES, Maisons-Alfort, France
| | - Audrey Fraisse
- Laboratory for Food Safety, Université Paris Est, ANSES, Maisons-Alfort, France
| | | | - Laurent Guillier
- Laboratory for Food Safety, Université Paris Est, ANSES, Maisons-Alfort, France
| | - Sylvie Perelle
- Laboratory for Food Safety, Université Paris Est, ANSES, Maisons-Alfort, France
| | - Sandra Martin-Latil
- Laboratory for Food Safety, Université Paris Est, ANSES, Maisons-Alfort, France
| |
Collapse
|